Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 52 results
Filters: Author is Mellors, John W  [Clear All Filters]
Found 52 results.
Skip Alphabet Links A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

R

La Rosa AM, Harrison LJ, Taiwo B, et al. "Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study." Lancet HIV. 2016;3(6):e247-58.
Riddler SA, Zheng L, Durand CM, et al. "Randomized Clinical Trial to Assess the Impact of the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 on HIV-1 Persistence in Individuals on Effective ART." Open Forum Infect Dis. 2018;5(10):ofy242.
Hammer SM, Ribaudo H, Bassett R, et al. "A randomized, placebo-controlled trial of abacavir intensification in HIV-1-infected adults with virologic suppression on a protease inhibitor-containing regimen." HIV Clin Trials. 2010;11(6):312-24.
Collier AC, Tierney C, Downey GF, et al. "Randomized study of dual versus single ritonavir-enhanced protease inhibitors for protease inhibitor-experienced patients with HIV." HIV Clin Trials. 2008;9(2):91-102.
Benson CA, Vaida F, Havlir DV, et al. "A randomized trial of treatment interruption before optimized antiretroviral therapy for persons with drug-resistant HIV: 48-week virologic results of ACTG A5086." J. Infect. Dis.. 2006;194(9):1309-18.
Wilkin TJ, McKinnon JE, A DiRienzo G, et al. "Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomes." J. Infect. Dis.. 2009;199(6):866-71.
Swindells S, A DiRienzo G, Wilkin T, et al. "Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression." JAMA. 2006;296(7):806-14.
Gandhi RT, Bosch RJ, Aga E, et al. "Residual plasma viraemia and infectious HIV-1 recovery from resting memory CD4 cells in patients on antiretroviral therapy: results from ACTG A5173." Antivir. Ther. (Lond.). 2013;18(4):607-13.
Clark SA, Shulman NS, Bosch RJ, Mellors JW. "Reverse transcriptase mutations 118I, 208Y, and 215Y cause HIV-1 hypersusceptibility to non-nucleoside reverse transcriptase inhibitors." AIDS. 2006;20(7):981-4.
Boltz VF, Zheng Y, Lockman S, et al. "Role of low-frequency HIV-1 variants in failure of nevirapine-containing antiviral therapy in women previously exposed to single-dose nevirapine." Proc. Natl. Acad. Sci. U.S.A.. 2011;108(22):9202-7.

Pages